- Title
- Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262
- Creators
- B.J. Monk - University of ArizonaH. Huang - Gynecologic Oncology GroupR.T. Penson - Massachusetts General HospitalS.A. Davidson - University of Colorado DenverM.L. Pearl - Stony Brook University HospitalD.M. O'Malley - The Ohio State UniversityD.P. Bender - University of Iowa Hospitals and ClinicsM.P. Boente - Minnesota OncologyL.P. Martin - Fox Chase Cancer CenterJ.K. Chan - UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USAJ.L. Walker - University of OklahomaC.K. McCourt - Women & Infants Hospital of Rhode Island
- Publication Details
- Gynecologic oncology, Vol.133, pp.58-58
- Publisher
- Elsevier Inc
- Identifiers
- 991005968881802656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262
Gynecologic oncology, Vol.133, pp.58-58
06/2014
Metrics
1 Record Views